Comprehensive Epilepsy Panel

Last modified: Mar 21, 2018


  • Is a 283 gene panel that includes assessment of non-coding variants
  • Is ideal for patients with epilepsy. For patients aged 24-60 months living in Europe or the Middle East, please see the Paediatric Epilepsy? Look Beyond no cost program.

Analysis methods

  • PLUS
  • SEQ


3-4 weeks

Number of genes


Test code


CPT codes

SEQ 81302
SEQ 81404
SEQ 81405
DEL/DUP 81479


The Blueprint Genetics Comprehensive Epilepsy Panel (test code NE1001):

  • Is a 283 gene panel that includes assessment of selected non-coding disease-causing variants
  • Is available as PLUS analysis (sequencing analysis and deletion/duplication analysis), sequencing analysis only or deletion/duplication analysis only

ICD codes

Commonly used ICD-10 code(s) when ordering the Comprehensive Epilepsy Panel

ICD-10 Disease
G40.9 Epilepsy

Sample Requirements

  • EDTA blood, min. 1 ml
  • Purified DNA, min. 3μg
  • Saliva (Oragene DNA OG-500 kit)

Label the sample tube with your patient’s name, date of birth and the date of sample collection.

Note that we do not accept DNA samples isolated from formalin-fixed paraffin-embedded (FFPE) tissue.

Epilepsy is defined by recurrent, unprovoked seizures due to abnormal, synchronized neuronal firing in the brain. It is one of the most common neurological conditions. Approximately 20-30 % of epilepsy cases are caused by acquired conditions, but the remaining 70-80 % of cases are believed to be due to one or more genetic factors. The epilepsies can be broadly grouped into three classes: genetic generalized epilepsy (formerly idiopathic generalized epilepsy); focal epilepsy; and epileptic encephalopathy. There are then several specific syndromes within each class defined by differences in specific seizure types, electroencephalogram (EEG) patterns, magnetic resonance imaging (MRI) findings and age of onset and disease progression. Epilepsy is also one of the features of many multisystemic genetic syndromes and often occurs in neurodegenerative diseases.

Genes in the Comprehensive Epilepsy Panel and their clinical significance

Gene Associated phenotypes Inheritance ClinVar HGMD
ABAT GABA-transaminase deficiency AR 11 11
ABCD1* Adrenoleukodystrophy XL 64 658
ADAR Dyschromatosis symmetrica hereditaria, Aicardi-Goutières syndrome AD/AR 21 205
ADSL Adenylosuccinase deficiency AR 24 56
AFG3L2* Spastic ataxia, Spinocerebellar ataxia AD/AR 21 37
AGA Aspartylglucosaminuria AR 40 36
AIFM1 Deafness XL 27 23
AIMP1 Leukodystrophy, hypomyelinating AR 4 5
ALDH3A2 Sjogren-Larsson syndrome AR 47 104
ALDH5A1 Succinic semialdehyde dehydrogenase deficiency AR 10 69
ALDH7A1 Epilepsy, pyridoxine-dependent AR 43 112
ALG13 Congenital disorder of glycosylation XL 5 7
AMACR Alpha-methylacyl-CoA racemase deficiency, Bile acid synthesis defect AR 3 8
AMT Glycine encephalopathy AR 26 95
AP4B1 Spastic paraplegia 47, autosomal recessive AR 13 9
AP4E1 Stuttering, familial persistent, 1, Spastic paraplegia 51, autosomal recessive AR 4 12
AP4M1 Spastic paraplegia 50, autosomal recessive AR 9 6
AP4S1* Spastic paraplegia 52, autosomal recessive AR 4 7
APOPT1 Mitochondrial complex IV deficiency AR 4 5
ARG1 Hyperargininemia AR 16 54
ARHGEF9 Epileptic encephalopathy, early infantile XL 6 13
ARSA Metachromatic leukodystrophy AR 92 215
ARX Lissencephaly, Epileptic encephalopathy, Corpus callosum, agenesis of, with abnormal genitalia, Partington syndrome, Proud syndrome, Hydranencephaly with abnormal genitalia, Mental retardation XL 64 85
ASAH1 Spinal muscular atrophy with progressive myoclonic epilepsy, Farber lipogranulomatosis AR 11 56
ASNS* Asparagine synthetase deficiency AR 16 15
ASPA Aspartoacylase deficiency (Canavan disease) AR 37 102
ATP1A3 Alternating hemiplegia of childhood, Dystonia 12 AD 74 104
ATP13A2 Parkinson disease (Kufor-Rakeb syndrome) AR 17 37
ATRX Carpenter-Waziri syndrome, Alpha-thalassemia/mental retardation syndrome, Holmes-Gang syndrome, Juberg-Marsidi syndrome, Smith-Fineman-Myers syndrome, Mental retardation-hypotonic facies syndrome XL 54 155
BRAT1 Rigidity and multifocal seizure syndrome, lethal neonatal AR 15 16
BTD Biotinidase deficiency AR 183 235
CACNA1A Migraine, familial hemiplegic, Episodic ataxia, Spinocerebellar ataxia 6, Epileptic encephalopathy, early infantile, 42 AD 93 203
CACNA1H Childhood absence epilepsy AD 9 43
CACNB4 Episodic ataxia AD 2 7
CASK Mental retardation and microcephaly with pontine and cerebellar hypoplasia, FG syndrome, Mental retardation XL 67 87
CASR Hypocalcemia, Neonatal hyperparathyroidism, Familial Hypocalciuric hypercalcemia with transient Neonatal hyperparathyroidism AD/AR 95 392
CC2D1A Mental retardation, autosomal recessive 3 AR 2 5
CDKL5 Epileptic encephalopathy, early infantile, Rett syndrome, atypical, Angelman-like syndrome XL 266 280
CERS1 Epilepsy, progressive myoclonic AR 9 1
CHD2 Epileptic encephalopathy, childhood-onset AD 57 43
CHRNA2 Epilepsy, nocturnal frontal lobe AD 1 6
CHRNA4 Epilepsy, nocturnal frontal lobe AD 7 14
CHRNB2 Epilepsy, nocturnal frontal lobe AD 8 12
CLCN2 Leukoencephalopathy with ataxia, Epilepsy AD/AR 19 22
CLCN4 Mental retardation, X-linked 49 19 9
CLN3 Neuronal ceroid lipofuscinosis, type 3 AR 85 70
CLN5 Neuronal ceroid lipofuscinosis, type 5 AR 47 43
CLN6 Neuronal ceroid lipofuscinosis, type 6 AR 25 81
CLN8 Neuronal ceroid lipofuscinosis, type 8 AR 34 41
CNTNAP2 Pitt-Hopkins like syndrome, Cortical dysplasia-focal epilepsy syndrome AR 35 67
COL4A1 Schizencephaly, Anterior segment dysgenesis with cerebral involvement, Retinal artery tortuosity, Porencephaly, Angiopathy, hereditary, with nephropathy, aneurysms, and muscle cramps, Brain small vessel disease AD 46 97
COX6B1 Mitochondrial complex IV deficiency AR 2 3
COX15 Leigh syndrome, Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency AR 7 5
CPT2 Carnitine palmitoyltransferase II deficiency AR 47 104
CSF1R Leukoencephalopathy, diffuse hereditary, with spheroids AD 55 73
CSTB Epilepsy, progressive myoclonic AR 17 15
CTC1 Cerebroretinal microangiopathy with calcifications and cysts AR 15 29
CTSD Ceroid lipofuscinosis, neuronal AR 13 14
CTSF Neuronal ceroid lipofuscinosis AR 8 9
CUL4B Mental retardation, syndromic, Cabezas XL 16 36
CYP27A1 Cerebrotendinous xanthomatosis AR 57 108
D2HGDH D-2-hydroxyglutaric aciduria 1 AR 10 32
DARS Hypomyelination with brainstem and spinal cord involvement and leg spasticity AR 9 14
DARS2 Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation AR 22 59
DCX Lissencephaly, Subcortical laminal heterotopia XL 126 138
DDC Aromatic l-amino acid decarboxylase deficiency AR 11 51
DEPDC5 Epilepsy, familial focal, with variable foci AD 57 70
DHFR* Megaloblastic anemia due to dihydrofolate reductase deficiency AR 2 5
DNAJC5 Kufs disease,, Ceroid lipofuscinosis, neuronal 4, Parry AD 2 2
DNM1* Epileptic encephalopathy, early infantile AD 19 19
DNM1L Encephalopathy due to defective mitochondrial and peroxisomal fission 1 AD 14 17
DOCK7 Epilepitic encephalopathy AR 13 4
DPYD 5-fluorouracil toxicity AD/AR 52 88
DPYS Dihydropyriminidase deficiency AR 8 24
EARS2 Combined oxidative phosphorylation deficiency AR 12 29
ECHS1 Mitochondrial short-chain enoyl-CoA hydratase 1 deficiency AR 17 30
ECM1 Lipoid proteinosis AR 13 61
EEF1A2 Epileptic encephalopathy, early infantile, Mental retardation AD 10 10
EFHC1 Epilepsy, myoclonic juvenile, Epilepsy, severe intractable, Epilepsy, juvenile absence AD/AR 5 34
EIF2B1 Leukoencephalopathy with vanishing white matter, Ovarioleukodystrophy AR 7 9
EIF2B2 Leukoencephalopathy with vanishing white matter, Ovarioleukodystrophy AR 9 27
EIF2B3 Leukoencephalopathy with vanishing white matter, Ovarioleukodystrophy AR 6 21
EIF2B4 Leukoencephalopathy with vanishing white matter, Ovarioleukodystrophy AR 8 30
EIF2B5 Leukoencephalopathy with vanishing white matter, Ovarioleukodystrophy AR 20 96
EPM2A Epilepsy, progressive myoclonic AR 15 74
ETFA Glutaric aciduria, Multiple acyl-CoA dehydrogenase deficiency AR 8 27
ETFB Glutaric aciduria, Multiple acyl-CoA dehydrogenase deficiency AR 6 14
ETFDH Glutaric aciduria, Multiple acyl-CoA dehydrogenase deficiency AR 37 169
ETHE1 Ethylmalonic encephalopathy AR 16 35
FA2H Spastic paraplegia AR 14 41
FAM126A Leukodystrophy, hypomyelinating AR 7 12
FAR1* Peroxisomal fatty acyl-CoA reductase 1 disorder AR 4 4
FARS2 Combined oxidative phosphorylation deficiency 14, Spastic paraplegia 77, autosomal recessive AR 15 15
FGF12 Epileptic encephalopathy, early infantile, 47 5 8
FH Hereditary leiomyomatosis and renal cell cancer AD/AR 142 174
FLNA Frontometaphyseal dysplasia, Osteodysplasty Melnick-Needles, Otopalatodigital syndrome type 1, Otopalatodigital syndrome type 2, Terminal osseous dysplasia with pigmentary defects XL 102 220
FOLR1 Cerebral folate deficiency AR 8 27
FOXG1 Rett syndrome, congenital variant AD 81 124
FOXRED1 Leigh syndrome, Mitochondrial complex I deficiency AR 12 7
GABRA1 Epileptic encephalopathy, early infantile, Epilepsy, childhood absence, Epilepsy, juvenile myoclonic AD 21 30
GABRB2 Epileptic encephalopathy AD 10 7
GABRB3 Epilepsy, childhood absence AD 14 41
GABRG2 Generalized epilepsy with febrile seizures plus, Familial febrile seizures, Dravet syndrome, Epilepsy, childhood absence AD 23 32
GALC Krabbe disease AR 66 233
GAMT Guanidinoacetate methyltransferase deficiency AR 16 55
GCDH Glutaric aciduria AR 64 205
GCH1 Dopa-Responsive Dystonia Hyperphenylalaninemia, BH4-deficient, GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia AD/AR 28 234
GFAP Alexander disease AD 114 128
GFM1 Combined oxidative phosphorylation deficiency AR 17 18
GJC2 Spastic paraplegia, Lymphedema, hereditary, Leukodystrophy, hypomyelinating AD/AR 22 54
GLB1 GM1-gangliosidosis, Mucopolysaccharidosis (Morquio syndrome) AR 60 212
GLDC Glycine encephalopathy AR 95 423
GLRB Hyperekplexia 2 AR 3 18
GNAO1 Epileptic encephalopathy, early infantile AD 24 25
GNB1 Mental retardation, autosomal dominant 42 11 23
GNE Inclusion body myopathy, Nonaka myopathy, Sialuria AD/AR 50 200
GOSR2* Epilepsy, progessive myoclonic AR 5 2
GPHN Hyperekplexia, Molybdenum cofactor deficiency AD/AR 25 20
GRIA3 Mental retardation XL 10 17
GRIK2 Mental retardation, autosomal recessive 6 AR 2 7
GRIN1 Mental retardation, autosomal dominant 8 AD 20 26
GRIN2A Epilepsy, focal, with speech disorder AD 47 81
GRIN2B Epileptic encephalopathy, early infantile, Mental retardation AD 54 50
GRN Frontotemporal lobar degeneration with TDP43 inclusions, GRN-related, Neuronal ceroid lipofuscinosis AD/AR 25 173
GTPBP3 Combined oxidative phosphorylation deficiency 23 AR 8 15
HACE1 Spastic paraplegia and psychomotor retardation with or without seizures 8 10
HCN1 Epileptic encephalopathy, early infantile AD 10 10
HECW2 Neurodevelopmental disorder with hypotonia, seizures, and absent language 6 4
HEPACAM Megalencephalic leukoencephalopathy with subcortical cysts, remitting AD/AR 12 25
HIBCH 3-hydroxyisobutryl-CoA hydrolase deficiency AR 14 13
HNRNPU Intellectual disability and seizures AD 19 55
HSD17B10 17-beta-hydroxysteroid dehydrogenase X deficiency, Mental retardation, syndromic XL 9 12
HSPD1* Spastic paraplegia, Leukodystrophy, hypomyelinating AD/AR 4 4
HTRA1 Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy type 2 (CADASIL2), Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) AR 16 27
HTT Huntington disease AD 8 7
IBA57 Multiple mitochondrial dysfunctions syndrome 3, Spastic paraplegia 74, autosomal recessive AR 3 10
IQSEC2 Mental retardation XL 38 44
KCNA1 Episodic ataxia/myokymia syndrome AD 22 40
KCNA2 Epileptic encephalopathy, early infantile AD 10 12
KCNB1 Early infantile epileptic encephalopathy AD 13 12
KCNC1 Epilepsy, progressive myoclonic AD 4 2
KCNH1 Temple-Baraitser syndrome, Zimmermann-Laband syndrome 1 AD/AR 13 12
KCNQ2 Epileptic encephalopathy, early infantile, Benign familial neonatal seizures, Myokymia AD 292 235
KCNQ3 Seizures, benign neonatal AD 16 17
KCNT1 Epilepsy, nocturnal frontal lobe AD 30 33
KCTD7* Epilepsy, progressive myoclonic AR 12 16
KDM5C Mental retardation, syndromic, Claes-Jensen XL 36 48
KIF1A Spastic paraplegia, Neuropathy, hereditary sensory, Mental retardation AD/AR 52 35
L2HGDH L-2-hydroxyglutaric aciduria AR 11 75
LGI1 Epilepsy, familial temporal lobe AD 23 49
LMNB1 Leukodystrophy, demyelinating, adult-onset, autosomal dominant AD 2 34
LRPPRC Leigh syndrome, French-Canadian type AR 19 12
LYRM7# Mitochondrial complex III deficiency, nuclear type 8 AR 5 7
MAGI2 Nephrotic syndrome 15 7 24
MARS2 Combined oxidative phosphorylation deficiency AR 7 5
MBD5 Mental retardation AD 40 81
MECP2 Angelman-like syndrome, Autism, Rett syndrome, Encephalopathy, Mental retardation XL 465 968
MED12 Ohdo syndrome, Mental retardation, with Marfanoid habitus, FG syndrome, Opitz-Kaveggia syndrome, Lujan-Fryns syndrome XL 24 26
MEF2C Mental retardation AD 31 71
MFSD8 Ceroid lipofuscinosis, neuronal AR 19 43
MLC1 Megalencephalic leukoencephalopathy with subcortical cysts AR 29 108
MOCS1* Molybdenum cofactor deficiency AR 7 32
MRPL44 Combined oxidative phosphorylation deficiency 16 AR 2 2
MTFMT Combined oxidative phosphorylation deficiency 15 AR 13 16
MTHFR Homocystinuria due to MTHFR deficiency AR 57 119
MTOR Smith-Kingsmore syndrome AD 24 16
NACC1 Neurodevelopmental disorder with epilepsy, cataracts, feeding difficulties, and delayed brain myelination (NECFM) 2
NDUFAF5 Mitochondrial complex I deficiency AR 10 11
NDUFAF6 Mitochondrial complex I deficiency, Leigh syndrome AR 13 8
NDUFS2 Mitochondrial complex I deficiency AR 4 22
NDUFS4 Mitochondrial complex I deficiency, Leigh syndrome AR 7 16
NDUFS7 Mitochondrial complex I deficiency, Leigh syndrome AR 5 7
NDUFS8 Mitochondrial complex I deficiency, Leigh syndrome AR 13 12
NDUFV1 Mitochondrial complex I deficiency AR 18 34
NECAP1* Epileptic encephalopathy, early infantile AR 1 1
NEU1 Sialidosis AR 22 59
NFU1 Multiple mitochondrial dysfunctions syndrome 1 AR 4 14
NHLRC1 Epilepsy, progressive myoclonic AR 14 70
NOTCH3 Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), Lateral meningocele syndrome AD 26 325
NRXN1 Pitt-Hopkins like syndrome, Schizophrenia AD/AR 80 304
NUBPL Mitochondrial complex I deficiency AR 9 9
OFD1 Simpson-Golabi-Behmel syndrome, Retinitis pigmentosa, Orofaciodigital syndrome, Joubert syndrome XL 133 156
OPHN1 Mental retardation, with cerebellar hypoplasia and distinctive facial appearance XL 23 35
PCDH19 Epileptic encephalopathy, early infantile XL 87 156
PGK1 Phosphoglycerate kinase 1 deficiency XL 15 26
PHF6 Borjeson-Forssman-Lehmann syndrome XL 18 29
PIGA* Multiple congenital anomalies-hypotonia-seizures syndrome XL 23 17
PIGN* Multiple congenital anomalies-hypotonia-seizures syndrome 1 AR 21 29
PIGO Hyperphosphatasia with mental retardation syndrome 2 AR 10 19
PIGT Multiple congenital anomalies-hypotonia-seizures syndrome 3 AR 6 9
PIGV Hyperphosphatasia with mental retardation syndrome 1 AR 8 15
PLCB1 Epileptic encephalopathy, early infantile AR 7 10
PLP1 Spastic paraplegia, Pelizaeus-Merzbacher disease XL 48 336
PNKP Epileptic encephalopathy, early infantile, Ataxia-oculomotor AR 31 17
PNPO Pyridoxamine 5'-phosphate oxidase deficiency AR 16 28
POLG POLG-related ataxia neuropathy spectrum disorders, Sensory ataxia, dysarthria, and ophthalmoparesis, Alpers syndrome, Progressive external ophthalmoplegia with mitochondrial DNA deletions, Mitochondrial DNA depletion syndrome AD/AR 92 274
POLR3A Leukodystrophy, hypomyelinating AR 29 85
POLR3B Leukodystrophy, hypomyelinating AR 17 56
PPT1* Ceroid lipofuscinosis, neuronal AR 84 77
PRICKLE1 Epilepsy, progressive myoclonic AD/AR 3 14
PRIMA1 Epilepsy, nocturnal frontal lobe AR
PRODH* Hyperprolinemia AR 41 10
PRRT2 Episodic kinesigenic dyskinesia AD 33 93
PSAP Krabbe disease, atypical, Metachromatic leukodystrophy due to saposin-b deficiency, Combined saposin deficiency, Gaucher disease, atypical, due to saposin C deficiency AR 16 24
PTS Hyperphenylalaninemia, BH4-deficient AR 16 90
PURA Mental retardation AD 47 26
PYCR2# Leukodystrophy, hypomyelinating 10 AR 9 12
QDPR Hyperphenylalaninemia, BH4-deficient AR 9 61
RAB39B Waisman parkinsonism-mental retardation syndrome, Mental retardation XL 5 14
RARS Leukodystrophy, hypomyelinating 9 AD 11 7
RELN Lissencephaly, Epilepsy, familial temporal lobe AD/AR 20 38
RMND1* Combined oxidative phosphorylation deficiency AR 15 15
RNASEH2A Aicardi-Goutières syndrome AR 13 21
RNASEH2B Aicardi-Goutières syndrome AR 10 40
RNASEH2C Aicardi-Goutières syndrome AR 6 14
RNASET2 Leukoencephalopathy, cystic, without megalencephaly AR 7 10
RNF216* Cerebellar ataxia and hypogonadotropic hypogonadism (Gordon Holmes syndrome) AR 10 12
ROGDI Kohlschutter-Tonz syndrome AR 9 12
SAMHD1 Aicardi-Goutières syndrome AR 22 51
SCARB2 Epilepsy, progressive myoclonic AR 22 24
SCN1A Migraine, familial hemiplegic, Epileptic encephalopathy, early infantile, Generalized epilepsy with febrile seizures plus, Early infantile epileptic encephalopathy 6, Generalized epilepsy with febrile seizures plus, type 2 , Febrile seizures, familial 3A AD 597 1459
SCN1B Atrial fibrillation, Brugada syndrome, Generalized epilepsy with febrile seizures plus AD 15 23
SCN2A Epileptic encephalopathy, early infantile, Seizures, benign familial infantile AD 139 220
SCN8A Cognitive impairment, Epileptic encephalopathy, early infantile AD 85 69
SCN9A Paroxysmal extreme pain disorder AD/AR 41 104
SCO1 Mitochondrial complex IV deficiency AR 6 5
SDHAF1 Mitochondrial complex II deficiency AR 4 6
SERAC1 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome AR 18 24
SERPINI1 Encephalopathy, familial, with neuroserpin inclusion bodies AD 5 8
SIK1 Epileptic encephalopathy, early infantile AD 5 6
SLC2A1 Stomatin-deficient cryohydrocytosis with neurologic defects, Epilepsy, idiopathic generalized, GLUT1 deficiency syndrome AD/AR 82 259
SLC6A1 Myoclonic-astastic epilepsy AD 22 17
SLC6A8* Creatine deficiency syndrome XL 25 124
SLC9A6 Mental retardation, syndromic, Christianson XL 22 19
SLC12A5 Epileptic encephalopathy, early infantile AR 3 12
SLC13A5 Epileptic encephalopathy, early infantile AR 15 19
SLC19A3 Thiamine metabolism dysfunction syndrome AR 24 24
SLC25A1 Combined D-2- and L-2-hydroxyglutaric aciduria AR 7 16
SLC25A15* Hyperornithinemia-hyperammonemia-homocitrullinemia syndrome AR 21 36
SLC25A22 Epileptic encephalopathy, early infantile AR 7 10
SLC35A2 Congenital disorder of glycosylation XL 13 15
SLC39A8 Congenital disorder of glycosylation, type IIn AR 7 6
SLC46A1 Folate malabsorption AR 17 20
SMS Mental retardation, Snyder-Robinson XL 10 11
SNAP25 Myasthenic syndrome, congenital AD 2 2
SNORD118 Leukoencephalopathy, brain calcifications, and cysts (Labrune syndrome) 6 35
SOX10 Peripheral demyelinating neuropathy, central dysmyelination, Waardenburg syndrome, and Hirschsprung disease AD 34 133
SPATA5 Schizophrenia AR 16 21
SPTAN1 Epileptic encephalopathy, early infantile AD 11 19
ST3GAL3 Epileptic encephalopathy, early infantile, Mental retardation AR 3 3
ST3GAL5 Ganglioside GM3 synthase deficiency AR 4 5
STX1B Generalized epilepsy with febrile seizures plus AD 7 9
STXBP1 Epileptic encephalopathy, early infantile AD 102 172
SUMF1 Multiple sulfatase deficiency AR 21 52
SUOX Sulfocysteinuria AR 6 28
SYN1 Epilepsy, with variable learning disabilities and behavior disorders XL 7 5
SYNGAP1 Mental retardation AD 54 63
SYNJ1 Epileptic encephalopathy, early infantile, 53, Parkinson disease 20, early-onset 8 23
SZT2 Epileptic encephalopathy, early infantile AR 9 9
TAF1 Dystonia 3, torsion, X-linked, Mental retardation, X-linked, syndromic 33 XL 11 14
TBC1D24 Deafness, Deafness, onychodystrophy, osteodystrophy, mental retardation, and seizures (DOORS) syndrome AD/AR 42 49
TBCD Early-onset progressive encephalopathy with brain atrophy and thin corpus callosum (PEBAT) 12 19
TBCE Progressive encephalopathy with amyotrophy and optic atrophy (PEAMO) AR 8 7
TBCK Hypotonia, infantile, with psychomotor retardation and characteristic facies 3 12 12
TBL1XR1* Mental retardation, autosomal dominant 41, Pierpont syndrome 16 17
TCF4 Corneal dystrophy, Fuchs endothelial, Pitt-Hopkins syndrome AD 67 136
TPP1 Spinocerebellar ataxia, Neuronal ceroid lipofuscinosis type 2 AR 52 110
TREX1 Vasculopathy, retinal, with cerebral leukodystrophy, Chilblain lupus, Aicardi-Goutières syndrome AD/AR 27 66
TSC1 Lymphangioleiomyomatosis, Tuberous sclerosis AD 106 336
TSC2 Lymphangioleiomyomatosis, Tuberous sclerosis AD 260 1093
TTC19 Mitochondrial complex III deficiency, nuclear type 2 AR 11 9
TUBB4A* Leukodystrophy, hypomyelinating, Dystonia AD 38 38
UBA5* Epileptic encephalopathy, early infantile, 44, Spinocerebellar ataxia, autosomal recessive 24 13 13
UBE2A Mental retardation, syndromic, Nascimento XL 6 22
UBE3A* Angelman syndrome AD 158 184
UNC80 Hypotonia, infantile, with psychomotor retardation and characteristic facies 2 20 12
VPS13A Choreoacanthocytosis AR 16 113
WDR26 Skraban-Deardorff syndrome 6 33
WDR45 Neurodegeneration with brain iron accumulation XL 28 67
WWOX Epileptic encephalopathy, early infantile, Spinocerebellar ataxia AR 30 36
YY1 Gabriele-de Vries syndrome (GADEVS) 7 23
ZEB2* Mowat-Wilson syndrome AD 117 270
ZFYVE26 Spastic paraplegia 15 AR 21 37

* Some, or all, of the gene is duplicated in the genome. Read more.

# The gene has suboptimal coverage (means <90% of the gene’s target nucleotides are covered at >20x with mapping quality score (MQ>20) reads).

The sensitivity to detect variants may be limited in genes marked with an asterisk (*) or number sign (#)

Gene refers to the HGNC approved gene symbol; Inheritance refers to inheritance patterns such as autosomal dominant (AD), autosomal recessive (AR), X-linked (XL), X-linked dominant (XLD) and X-linked recessive (XLR); ClinVar refers to the number of variants in the gene classified as pathogenic or likely pathogenic in this database (ClinVar); HGMD refers to the number of variants with possible disease association in the gene listed in Human Gene Mutation Database (HGMD). The list of associated, gene specific phenotypes are generated from CGD or Orphanet databases.

Non-coding variants covered by the panel

Gene Genomic location HG19 HGVS RefSeq RS-number
ADSL Chr22:40742514 c.-49T>C NM_000026.2
ALDH3A2 Chr17:19561044 c.681-14T>A/G NM_001031806.1
ALDH7A1 Chr5:125907053 c.696-502G>C NM_001182.4
AMT Chr3:49459938 c.-55C>T NM_000481.3 rs386833677
ARG1 Chr6:131901748 c.306-611T>C NM_000045.3
ARSA Chr22:51064121 c.1108-12C>G NM_000487.5 rs757806374
BTD Chr3:15687154 c.*159G>A NM_000060.2 rs530872564
CACNA1A Chr19:13341036 c.5404-13G>A NM_001127221.1
CASR Chr3:121994640 c.1378-19A>C NM_001178065.1
CDKL5 ChrX:18525053 c.-162-2A>G NM_003159.2 rs786204973
CLN3 Chr16:28497984 c.461-13G>C NM_000086.2 rs386833721
COL4A1 Chr13:110802679 c.*31G>T NM_001845.4
COL4A1 Chr13:110802678 c.*32G>T NM_001845.4
COL4A1 Chr13:110802675 c.*35C>A NM_001845.4
D2HGDH Chr2:242680425 c.293-23A>G NM_152783.3
DARS2 Chr1:173797449 c.228-21_228-20insC NM_018122.4 rs367543010
EIF2B5 Chr3:183855941 c.685-13C>G NM_003907.2
ETFDH Chr4:159593534 c.-75A>G NM_004453.2
FGF12 Chr3:191857076 c.*4722T>C NM_021032.4
GABRA1 Chr5:161274418 c.-248+1G>T NM_000806.5
GABRB3 Chr15:27020313 c.-2204G>A NM_000814.5
GABRB3 Chr15:27020399 c.-2290T>C NM_000814.5 rs546389769
GALC Chr14:88459917 c.-74T>A NM_001201402.1
GAMT Chr19:1399508 c.391+15G>T NM_138924.2 rs367567416
GCDH Chr19:13010271 c.1244-11A>G NM_000159.3
GJC2 Chr1:228337561 c.-167A>G NM_020435.3
GJC2 Chr1:228337558 c.-170A>G NM_020435.3
GJC2 Chr1:228337709 c.-20+1G>C NM_020435.3
GRN Chr17:42422705 c.-8+3A>T NM_002087.2 rs63751020
GRN Chr17:42422707 c.-8+5G>C NM_002087.2 rs63750313
GRN Chr17:42422701 c.-9A>G NM_002087.2
L2HGDH Chr14:50735527 c.906+354G>A NM_024884.2
MOCS1 Chr6:39874534 c.*365_*366delAG NM_005943.5 rs397518419
MTHFR Chr1:11863212 c.-13-28_-13-27delCT NM_005957.4 rs786204005
MTHFR Chr1:11850973 c.1753-18G>A NM_005957.4 rs777661576
NDUFAF6 Chr8:96046914 c.298-768T>C NM_152416.3 rs575462405
NDUFS7 Chr19:1386643 c.17-1167C>G NM_024407.4
NUBPL Chr14:32319298 c.815-27T>C NM_025152.2 rs118161496
OFD1 ChrX:13773245 c.1130-22_1130-19delAATT NM_003611.2 rs312262865
OFD1 ChrX:13768358 c.935+706A>G NM_003611.2 rs730880283
PLP1 ChrX:103042413 c.454-314T>A/G NM_000533.3
PLP1 ChrX:103042405 c.454-322G>A NM_000533.3
PNKP Chr19:50364799 c.1387-33_1386+49delCCTCCTCCCCTGACCCC NM_007254.3 rs752902474
POLR3A Chr10:79769277 c.1909+18G>A NM_007055.3 rs267608677
POLR3A Chr10:79769273 c.1909+22G>A NM_007055.3 rs191875469
POLR3B Chr12:106831447 c.1857-12A>G NM_018082.5 rs528038639
POLR3B Chr12:106804589 c.967-15A>G NM_018082.5
PPT1 Chr1:40539203 c.*526_*529delATCA NM_000310.3 rs386833624
PPT1 Chr1:40558194 c.125-15T>G NM_000310.3 rs386833629
PSAP Chr10:73583679 c.778-26C>A NM_001042465.1
PTS Chr11:112100215 c.164-716A>T NM_000317.2
PTS Chr11:112099026 c.84-291A>G NM_000317.2
PTS Chr11:112098994 c.84-323A>T NM_000317.2 rs794726657
QDPR Chr4:17500790 c.436+2552A>G NM_000320.2
RNASEH2B Chr13:51501530 c.65-13G>A NM_024570.3
SCN1A Chr2:166913031 c.384-21T>A NM_006920.4 rs373168416
SCN1A Chr2:166854699 c.4306-14T>G NM_006920.4
SCN1A Chr2:166848946 c.4820-14T>G NM_006920.4
SCN1A Chr2:166908215 c.964+14T>G NM_006920.4 rs794726837
SLC19A3 Chr2:228560811 c.980-14A>G NM_025243.3 rs200542114
SLC2A1 Chr1:43395462 c.680-11G>A NM_006516.2
SOX10 Chr22:38412215 c.-31954C>T NM_006941.3 rs606231342
SOX10 Chr22:38379877 c.-84-2A>T NM_006941.3
TBCD Chr17:80851411 c.1564-12C>G NM_005993.4
TPP1 Chr11:6637752 c.887-18A>G NM_000391.3
TSC2 Chr16:2098067 c.-30+1G>C NM_000548.3 rs587778004
TSC2 Chr16:2127477 c.2838-122G>A NM_000548.3
TSC2 Chr16:2138031 c.5069-18A>G NM_000548.3 rs45484794
TSC2 Chr16:2110656 c.976-15G>A NM_000548.3 rs45517150
ZEB2 Chr2:145274987 c.-69-1G>A NM_014795.3

Added and removed genes from the panel

Genes added Genes removed

Test strength

The strengths of this test include:
  • CAP and ISO-15189 accreditations covering all operations at Blueprint Genetics including all Whole Exome Sequencing, NGS panels and confirmatory testing
  • CLIA-certified personnel performing clinical testing in a CLIA-certified laboratory
  • Powerful sequencing technologies, advanced target enrichment methods and precision bioinformatics pipelines ensure superior analytical performance
  • Careful construction of clinically effective and scientifically justified gene panels
  • Our Nucleus online portal providing transparent and easy access to quality and performance data at the patient level
  • Our publically available analytic validation demonstrating complete details of test performance
  • 1479 non-coding disease causing variants in Blueprint WES assay (please see below ‘Non-coding disease causing variants covered by this panel’)
  • Our rigorous variant classification based on modified ACMG variant classification scheme
  • Our systematic clinical interpretation workflow using proprietary software enabling accurate and traceable processing of NGS data
  • Our comprehensive clinical statements

Test limitations

This panel does not detect the expansion of a 12-nucleotide repeat (rs193922905) in the promoter region of *CSTB*. The following exons are not included in the panel as they are not sufficiently covered with high quality sequence reads: *GABRB2* (10). Genes with suboptimal coverage in our assay are marked with number sign (#) and genes with partial, or whole gene, segmental duplications in the human genome are marked with an asterisk (*) if they overlap with the UCSC pseudogene regions. Gene is considered to have suboptimal coverage when >90% of the gene’s target nucleotides are not covered at >20x with mapping quality score (MQ>20) reads. The technology may have limited sensitivity to detect variants in genes marked with these symbols (please see the Panel content table above).

This test does not detect the following:
  • Complex inversions
  • Gene conversions
  • Balanced translocations
  • Mitochondrial DNA variants
  • Repeat expansion disorders unless specifically mentioned
  • Non-coding variants deeper than ±20 base pairs from exon-intron boundary unless otherwise indicated (please see above Panel Content / non-coding variants covered by the panel).

This test may not reliably detect the following:

  • Low level mosaicism
  • Stretches of mononucleotide repeats
  • Indels larger than 50bp
  • Single exon deletions or duplications
  • Variants within pseudogene regions/duplicated segments

The sensitivity of this test may be reduced if DNA is extracted by a laboratory other than Blueprint Genetics.

For additional information, please refer to the Test performance section and see our Analytic Validation.

The Blueprint Genetics comprehensive epilepsy panel covers classical genes associated with epilepsy, metabolic epilepsy, sudden unexpected death, leukoencephalopathy and neuronal ceroid lipofuscinosis. The genes on the panel have been carefully selected based on scientific literature, mutation databases and our experience.

Our panels are sliced from our high-quality whole exome sequencing data. Please see our sequencing and detection performance table for different types of alterations at the whole exome level (Table).

Assays have been validated for different starting materials including EDTA-blood, isolated DNA (no FFPE), saliva and dry blood spots (filter card) and all provide high-quality results. The diagnostic yield varies substantially depending on the assay used, referring healthcare professional, hospital and country. Blueprint Genetics’ Plus Analysis (Seq+Del/Dup) maximizes the chance to find a molecular genetic diagnosis for your patient although Sequence Analysis or Del/Dup Analysis may be a cost-effective first line test if your patient’s phenotype is suggestive of a specific mutation type.

Performance of Blueprint Genetics Whole Exome Sequencing (WES) assay. All individual panels are sliced from WES data.

Sensitivity % (TP/(TP+FN) Specificity %
Single nucleotide variants 99.65% (412,456/413,893) >99.99%
Insertions, deletions and indels by sequence analysis
1-10 bps 96.94% (17,070/17,608) >99.99%
11-50 bps 99.07% (957/966) >99.99%
Copy number variants (exon level dels/dups)
Clinical samples (small CNVs, n=52)
1 exon level deletion 92.3% (24/26) NA
2 exons level deletion/duplication 100.0% (11/11) NA
3-7 exons level deletion/duplication 93.3% (14/15) NA
Microdeletion/-duplication sdrs (large CNVs, n=37))
Size range (0.1-47 Mb) 100% (37/37)
Simulated CNV detection
2 exons level deletion/duplication 90.98% (7,357/8,086) 99.96%
5 exons level deletion/duplication 98.63% (7,975/8,086) 99.98%
The performance presented above reached by WES with the following coverage metrics
Mean sequencing depth at exome level 174x
Nucleotides with >20x sequencing coverage (%) 99.4%


The target region for each gene includes coding exons and ±20 base pairs from the exon-intron boundary. In addition, the panel includes non-coding variants if listed above (Non-coding variants covered by the panel). Some regions of the gene(s) may be removed from the panel if specifically mentioned in the ‘Test limitations” section above. The sequencing data generated in our laboratory is analyzed with our proprietary data analysis and annotation pipeline, integrating state-of-the art algorithms and industry-standard software solutions. Incorporation of rigorous quality control steps throughout the workflow of the pipeline ensures the consistency, validity and accuracy of results. Our pipeline is streamlined to maximize sensitivity without sacrificing specificity. We have incorporated a number of reference population databases and mutation databases such as, but not limited, to 1000 Genomes Project, gnomAD, ClinVar and HGMD into our clinical interpretation software to make the process effective and efficient. For missense variants, in silico variant prediction tools such as SIFT, PolyPhen, MutationTaster are used to assist with variant classification. Through our online ordering and statement reporting system, Nucleus, the customer has an access to details of the analysis, including patient specific sequencing metrics, a gene level coverage plot and a list of regions with inadequate coverage if present. This reflects our mission to build fully transparent diagnostics where customers have easy access to crucial details of the analysis process.

Clinical interpretation

We provide customers with the most comprehensive clinical report available on the market. Clinical interpretation requires a fundamental understanding of clinical genetics and genetic principles. At Blueprint Genetics, our PhD molecular geneticists, medical geneticists and clinical consultants prepare the clinical statement together by evaluating the identified variants in the context of the phenotypic information provided in the requisition form. Our goal is to provide clinically meaningful statements that are understandable for all medical professionals regardless of whether they have formal training in genetics.

Variant classification is the corner stone of clinical interpretation and resulting patient management decisions. Our classifications follow the Blueprint Genetics Variant Classification Schemes based on the ACMG guideline 2015. Minor modifications were made to increase reproducibility of the variant classification and improve the clinical validity of the report. Our experience with tens of thousands of clinical cases analyzed at our laboratory allowed us to further develop the industry standard.

The final step in the analysis of sequence variants is confirmation of variants classified as pathogenic or likely pathogenic using bi-directional Sanger sequencing. Variant(s) fulfilling all of the following criteria are not Sanger confirmed: 1) the variant quality score is above the internal threshold for a true positive call, 2) an unambiguous IGV in-line with the variant call and 3) previous Sanger confirmation of the same variant at least three times at Blueprint Genetics. Reported variants of uncertain significance are confirmed with bi-directional Sanger sequencing only if the quality score is below our internally defined quality score for true positive call. Reported copy number variations with a size <10 exons are confirmed by orthogonal methods such as qPCR if the specific CNV has been seen less than three times at Blueprint Genetics.

Our clinical statement includes tables for sequencing and copy number variants that include basic variant information (genomic coordinates, HGVS nomenclature, zygosity, allele frequencies, in silico predictions, OMIM phenotypes and classification of the variant). In addition, the statement includes detailed descriptions of the variant, gene and phenotype(s) including the role of the specific gene in human disease, the mutation profile, information about the gene’s variation in population cohorts and detailed information about related phenotypes. We also provide links to the references used, congress abstracts and mutation databases to help our customers further evaluate the reported findings if desired. The conclusion summarizes all of the existing information and provides our rationale for the classification of the variant.

Identification of pathogenic or likely pathogenic variants in dominant disorders or their combinations in different alleles in recessive disorders are considered molecular confirmation of the clinical diagnosis. In these cases, family member testing can be used for risk stratification within the family. In the case of variants of uncertain significance (VUS), we do not recommend family member risk stratification based on the VUS result. Furthermore, in the case of VUS, we do not recommend the use of genetic information in patient management or genetic counseling. For eligible cases, Blueprint Genetics offers a no charge service to investigate the role of reported VUS (VUS Clarification Service).

Our interpretation team analyzes millions of variants from thousands of individuals with rare diseases. Thus, our database, and our understanding of variants and related phenotypes, is growing by leaps and bounds. Our laboratory is therefore well positioned to re-classify previously reported variants as new information becomes available. If a variant previously reported by Blueprint Genetics is re-classified, our laboratory will issue a follow-up statement to the original ordering health care provider at no additional cost.